Skip to content

Development of non-invasive treatment for Parkinson's disease with violet light

Development of non-invasive treatment for Parkinson's disease with violet light

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032200104
Enrollment
20
Registered
2020-09-01
Start date
2021-05-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

Sponsors

Genko Oyama
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Patients diagnosed with Parkinson's disease according to MDS clinical diagnostic criteria for Parkinson's disease 2)Patients who have not changed or added any of the settings of levodopa preparation, dopamine agonist, antiparkinsonism drug, deep brain stimulator (DBS) within 4 weeks before obtaining consent 3)Patients with Modified Hoehn & Yahr severity of 4 degrees or less (4 degrees or less when off if there is a wear-off) 4)Patients with visual hallucinations (noise parade rear test 1 point or more) 5)It does not matter whether the patient is hospitalized or outpatient (outpatient preferred) 6)Patients who can assist wearing violet light irradiation goggles 7)Patients who can spend 3 hours in the daytime (11:00 to 14:00 as a guide) with the naked eyes when wearing violet light irradiation goggles 8)Men and women over the age of 20 9)Patients with written informed consent to participate in this study

Exclusion criteria

Exclusion criteria: 1)Patients on continuous levodopa-carbidopa intestinal gel (LCIG) within 4 weeks before obtaining consent 2)Patients with epilepsy, severe heart, lung, kidney, liver or digestive disorders 3)Patients with severe cataract (nuclear sclerosis grade 3 or more) 4)Patient who performed ophthalmic surgery within 6 months before obtaining consent 5)Patients with retinal abnormalities such as serous retinal detachment and retinal hemorrhage 6)Patients with a history of seizures or epilepsy 7)Patients with a history of cancer or patients with serious diseases such as cancer 8)Patients who are pregnant or breastfeeding 9)Other patients who are judged to be unsuitable by the investigator

Design outcomes

Primary

MeasureTime frame
Evaluation of safety by ophthalmic examination

Secondary

MeasureTime frame
Evaluation of Parkinson's disease symptoms using various evaluation scales Status of occurrence of adverse events and failures

Contacts

Public ContactOyama Genko

Juntendo University Hospital

g_oyama@juntendo.ac.jp+81-3-3813-3111-70658

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026